Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Craig A. Tooman M.B.A. | President, CEO & Executive Director | 1.56M | -- | 1965 |
| Ms. Rhonda L. Hellums | Executive VP, CFO & Secretary | 947.8k | -- | 1972 |
| Dr. Steven J. Romano M.D. | Executive VP and Chief Research & Development Officer | 692.29k | -- | 1959 |
| Dr. Marie Wikstrom Lindholm Ph.D. | Chief Scientific Officer | -- | -- | -- |
| Ms. Gem Gokmen Hopkins | Head of IR & Corporate Communications | -- | -- | -- |
| Ms. Gianine Esposito | Chief Human Resources Officer | -- | -- | -- |
| Dr. Barbara A. Ruskin J.D., Ph.D. | Senior VP and Chief Intellectual Property & Innovation Officer | -- | -- | 1960 |
| Dr. Eric Floyd M.B.A., M.S., Ph.D. | Senior Vice President of Regulatory Affairs & Quality Assurance | -- | -- | 1963 |
| Mr. J.P. Gabriel | Chief Technical Operations Officer | -- | -- | -- |
| Mr. Curtis Rambaran M.D. | Chief Medical Officer | -- | -- | -- |
Silence Therapeutics plc
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 109
Description
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available